Today
+0.22%
5 Days
+1.99%
1 Month
+11.34%
6 Months
-6.17%
Year to Date
-19.55%
1 Year
-19.90%
Abbott Laboratories's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 10 out of 200 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 120.25.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
Abbott Laboratories is an American multinational health care and medical devices corporation headquartered in Abbott Park, Illinois. Founded in 1888 by Chicago physician Wallace Calvin Abbott, the company initially focused on formulating known drugs. Today, it offers medical devices, diagnostics, branded generic medications, and nutritional products. In 2013, Abbott separated its research-based pharmaceuticals division into AbbVie.
Abbott's product lineup includes Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip.
Abbott Laboratories is an American multinational health care and medical devices corporation headquartered in Abbott Park, Illinois. Founded in 1888 by Chicago physician Wallace Calvin Abbott, the company initially focused on formulating known drugs. Today, it offers medical devices, diagnostics, branded generic medications, and nutritional products. In 2013, Abbott separated its research-based pharmaceuticals division into AbbVie.
Abbott's product lineup includes Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip.
Related Instruments
Popular Instruments
